OLABIMPE LABIYI: Open Payments
NPI 1548973852 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,179 in 94 payments from 12 companies in 2025. Trend: 2023 $738 · 2024 $1,133 · 2025 $2,179
Food & beverage: $2,179
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $419 |
| Otsuka America Pharmaceutical, Inc. | 15 | $370 |
| E.R. Squibb & Sons, L.L.C. | 9 | $268 |
| ABBVIE INC. | 13 | $235 |
| Teva Pharmaceuticals USA, Inc. | 12 | $214 |
| Axsome Therapeutics, Inc. | 7 | $178 |
| Vanda Pharmaceuticals Inc. | 9 | $149 |
| Supernus Pharmaceuticals, Inc. | 3 | $141 |
| Neurocrine BioSciences, Inc. | 4 | $114 |
| Janssen Pharmaceuticals, Inc | 2 | $61 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, Auvelity, AUSTEDO XR, FANAPT, Qelbree.
Industry payments across TX — which companies pay providers there.
